A new article punished in the International Journal of Pharmaceutics describes the “Bacteriophage endolysin powders for inhaled delivery against pulmonary infections” by Wang et al. https://doi.org/10.1016/j.ijpharm.2023.122679
Abstract
Endolysins are bacteriophage-encoded enzymatic proteins that have great potential to treat multidrug-resistant bacterial infections. Bacteriophage endolysins Cpl-1 and ClyJ-3 have shown promising antimicrobial activity against Streptococcus pneumoniae, which causes pneumonia in humans. This is the first study to investigate the feasibility of spray-dried endolysins Cpl-1 and ClyJ-3 with excipients to produce inhalable powders. The two endolysins were individually tested with leucine and sugar (lactose or trehalose) for spray drying method followed by characterization of biological and physico-chemical properties. A complete loss of ClyJ-3 bioactivity was observed after atomization of the liquid feed solution（before the drying process）, while Cpl-1 maintained its bioactivity in the spray-dried powders. Cpl-1 formulations containing leucine with lactose or trehalose showed promising physico-chemical properties (particle size, crystallinity, hygroscopicity, etc.) and aerosol performances (fine particle fraction values above 65%). The results indicated that endolysin Cpl-1 can be formulated as spray dry powders suitable for inhaled delivery to the lungs for the potential treatment of pulmonary infections.
https://www.sciencedirect.com/science/article/abs/pii/S0378517323000996#f0050
PHAGElogist 